---
title: "Faeth Therapeutics Q2 FY26 net loss widens to $16.01 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294815845.md"
description: "Faeth Therapeutics reported a widened Q2 FY26 net loss of $16.01 million ($2.84 per share), driven by doubled R&D and G&A expenses. Cash reserves rose to $186.4 million. The company dosed its first patient in the Phase 1b/2 PIK-101 breast cancer trial in April, with topline data from the PIK-201 endometrial cancer trial expected by year-end and initial PIK-101 results anticipated in 2027."
datetime: "2026-08-04T11:30:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294815845.md)
  - [en](https://longbridge.com/en/news/294815845.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294815845.md)
generator: "portal-rs"
---

# Faeth Therapeutics Q2 FY26 net loss widens to $16.01 million

-   Faeth Therapeutics posted a net loss of $16.01 million, or $2.84 per share, for the quarter ended June 30, 2026. \* R&D expense more than doubled to $9.18 million; G&A expense more than doubled to $9.21 million. \* Cash, cash equivalents, and marketable securities climbed to $186.4 million as of June 30, 2026. \* First patient dosed in the Phase 1b/2 PIK-101 trial in HR+/HER2- advanced breast cancer in April. \* Topline data from the Phase 2 PIK-201 endometrial cancer trial expected by year-end; initial PIK-101 safety and efficacy data expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804105795) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)

## Related News & Research

- [Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FTH Stock News](https://longbridge.com/en/news/297318443.md)
- [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md)
- [Igua Sergipe board signs off Q2 2026 financial results](https://longbridge.com/en/news/297932404.md)
- [J.M. Smucker announces dividend of R$ 1.94 per unit for Q3 2026](https://longbridge.com/en/news/297931100.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**